Intellia’s in vivo CRISPR therapy lonvo-z succeeded in a Phase 3 trial for hereditary angioedema, sharply reducing attack rates in patients with the rare swelling disorder. Intellia said it started a rolling submission for regulatory review. In the Phase 3 study of 80 patients, lonvo-z reduced attack rates by 87% versus placebo. More than 60% of treated patients were attack-free over the study period, compared with 11% on placebo, and Intellia reported no serious safety signals. The company characterized the results as positioning the therapy for market as a “functional cure” or major upgrade relative to existing options. The update also adds a second in vivo CRISPR program track after Vertex’s Casgevy, raising expectations for broader CRISPR adoption.